 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || deuterated S-avadomide (SP-3164) / Salarius
Trial completion date, Trial initiation date, Trial primary completion date: Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 22, 2023
P1, N=72, Not yet recruiting, Sponsor: Salarius Pharmaceuticals, LLC
Trial completion date: Aug 2026 --> Aug 2027 | Initiation date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2024 --> Aug 2025
- ||| deuterated S-avadomide (SP-3164) / Salarius
New P1 trial: Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 7, 2023
P1, N=72, Not yet recruiting, Sponsor: Salarius Pharmaceuticals, LLC
- deuterated S-avadomide (SP-3164) / Salarius
A NOVEL CEREBLON-BINDING MOLECULAR GLUE, SP-3164, SHOWS PRECLINICAL ACTIVITY IN NON-HODGKIN LYMPHOMAS (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1534;
Further assessment of SP-3164's potential as a treatment for NHLs is warranted and a clinical trial is planned to start in 2023. Non-Hodgkin's lymphoma, Immunomodulation, B cell lymphoma
- deuterated S-avadomide (SP-3164) / Salarius
SP-3164, a novel molecular glue degrader with activity in preclinical models of multiple myeloma (Section 19; Poster Board #23) - Mar 14, 2023 - Abstract #AACR2023AACR_8455;
In vivo, SP-3164 has superior single agent and combination activity compared to approved molecular glues. These data support the continued development as a novel therapy in MM.
- deuterated S-avadomide (SP-3164) / Salarius
SP-3164, a novel ikaros and aiolos molecular glue degrader with preclinical activity in non-Hodgkin lymphomas (Section 18; Poster Board #24) - Mar 14, 2023 - Abstract #AACR2023AACR_2580;
SP-3164 is a novel, orally available, CRBN-binding molecular glue with desirable therapeutic properties and significant anticancer activity in NHL models. Further assessment of SP-3164
- deuterated S-avadomide (SP-3164) / Salarius
SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_5801;
SP-3164 showed increased IKZF1 degradation efficiency compared to other molecular glues and significant anti-cancer activity as a monotherapy in an in vivo lymphoma mouse xenograft model. Future studies will evaluate SP-3164 efficacy and direct potential combinations to support clinical development of SP-3164 in DLBCL and other non-Hodgkin’s lymphomas.